Hirschmann R, Yao W, Cascieri M A, Strader C D, Maechler L, Cichy-Knight M A, Hynes J, van Rijn R D, Sprengeler P A, Smith A B
Department of Chemistry, University of Pennsylvania, Philadelphia 19104, USA.
J Med Chem. 1996 Jun 21;39(13):2441-8. doi: 10.1021/jm960281e.
The endogenous peptides somatostatin (SRIF) and substance P comprise very different structures. Although both bind G-protein-coupled receptors, the SRIF receptors (SSTR 1-5) recognize SRIF and related peptides which retain its beta-turn such as the potent cyclic hexapeptide SRIF agonist L-363,301 (6a), but not substance P. Conversely the NK-1 receptor binds substance P but not the above ligands. In contrast, the beta-D-glucosides 1 and 2, designed to mimic the beta-turn of 6a, bind both receptors. This observation led us to attempt the conversion of 6a into the first potent, selective cyclic hexapeptide ligand for the NK-1 receptor. To this end, we combined design with a minilibrary approach. The goal was accomplished with surprising ease, leading to the NK-1 receptor antagonist 9 (IC50 2.0 +/- 0.4 nM). This demonstrates that peptidomimetics, incorporating in this case the promiscuous beta-D-glucose scaffold, can provide valuable clues about receptor similarities not revealed by their endogenous ligands. In addition, this work suggests that the use of libraries and rational design need not be mutually exclusive approaches to lead discovery.
内源性肽类物质生长抑素(SRIF)和P物质具有截然不同的结构。尽管二者均与G蛋白偶联受体结合,但SRIF受体(SSTR 1 - 5)识别SRIF及保留其β-转角结构的相关肽类,如强效环状六肽SRIF激动剂L - 363,301(6a),却不识别P物质。相反,NK - 1受体结合P物质而不结合上述配体。相比之下,设计用于模拟6a的β-转角结构的β-D-葡萄糖苷1和2能与这两种受体结合。这一观察结果促使我们尝试将6a转化为首个对NK - 1受体具有强效、选择性的环状六肽配体。为此,我们将设计与微型文库方法相结合。这一目标出人意料地轻松达成,得到了NK - 1受体拮抗剂9(IC50为2.0±0.4 nM)。这表明在这种情况下,结合了通用β-D-葡萄糖支架的拟肽可以提供有关受体相似性的有价值线索,而这些线索是其内源配体所未揭示的。此外,这项工作表明文库的使用和合理设计并非相互排斥的先导化合物发现方法。